Hakan PARLAKPİNARL, Mustafa SAĞIRL, Mehmet Hamdi ÖRÜM

Kardiyovasküler Sistemde Anjiyotensin II Tip reseptörü (AT2) ve Agonistleri

Anjiyotensin renin anjiyotensin sisteminin etkili bir peptididir. Gelişimsel, fizyolojik ve patolojik süreçler içerisinde hücresel büyümeyi düzenleyen Anjiotensin ll' nin ATı ve AT2 olmak üzere başlıca iki reseptör alt tipi vardır. Kardiyovasküler hemodinami ve yapının düzenlemesinde Anjiotensin ll' nin önemli bir role sahip olduğu iyi bir şekilde ortaya konulmuştur. Anjiotensin , kardiyovasküler sistem üzerindeki pek çok etkisini ATı reseptörü üzerinden gerçekleştirmekte olup, bu özelliği ile kardiyovasküler hastalıklarda yıllardır bir ilaç hedefi olarak kullanılmaktadır. Buna karşılık, AT2 reseptörünün katkısı ise çok fazla bilinmemekte ve sadece akademik bir ilgi alanı olarak kalmaktaydı. llk non-peptid AT2 reseptör agonisti compound 21' in sentezlenmesi ile bu durum değişti. Compound 21 kullanılarak yapılan çalışmalar miyokard infarktüsü sonrasında doku koruyucu ve fonksiyonel iyileştirici etkilerini ortaya çıkardı. Daha sonra kardiyovasküler sistemde AT2 reseptör aracılı etkilerin ortaya çıkarılması için çalışmalar yapılmaya devam edildi. Biz bu derlemede peptid (CGP42112A, novokinin) ve non--peptid (compound 21) AT2 reseptör agonistlerinin kardiyovasküler sistem üzerindeki etkilerini tartışacağız.

Angiotensin II Type Receptor (AT2) and Agonists in Cardiovascular System

Angiotensin II is an effector peptide of the renin angiotensin system. Angiotensin II which regulates cellular growth in response to developmental, physiological, and pathological processes has two main receptor subtypes which are the AT1 and AT2 receptor. It is well established that angiotensin || has an important role in regulating cardiovascular hemodynamics and structure. Most ofthe known effects of angiotensin II in cardiovascular system are attributable to the AT1 receptor, and it has been drug target in cardiovascular disease for many years. On the other hand, less was known about the AT2 receptor and it remained only an academic interest. This circumstance has changed with the synthesis of first non—peptide AT2 receptor agonist, compound 21. The studies using compound 21 indicated tissue protective effects and functional improvement after myocardial infarction. Then, the research has continued to reveal AT2 receptor mediated effects in cardiovascular system. Herein, we will discuss the role ofthe peptide (CGP42112A, novokinin) and the non—peptide (compound 21) AT2 receptor agonists in the cardiovascular system.

PDF

___

1. Georgiopoulou W, Kalogeropoulos AP, Butler J. Heart failure in hypertension: prevention and treatment. Drugs 2012;72(10):1373—98.
2. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the renin— angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763—70.
3. Parlakpinar H, Ozer MK, Acet A. Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia—reperfusion induced infarct size. Cytokine 2011;56:688—94.
4. Wright JW, Krebs LT, Stobb JW, Harding JW. The Angiotensin IV system: Functional implications. Front Neuroendocrinol 1995;16:23-52.
Hanesworth JM, Sardinia MF, Krebs LT, Hall KL, Harding JW. Elucidation of specific binding site for angiotensin (3—8), Angiotensin IV, in mammalian heart membranes. Pharmacol Exp Ther 1993;266:1036—53.
Benter LF, Ferrario CM, Morris M, Diz DL. Chronic intravenous angiotensin (1 —7) infusions activate antihypertensive mechanisms in spontaneously hypertensive rats. Am Hypertens 1994;7:H22.
Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathopysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000;52:641.
Lazard D, Villageois P, Briend—Sutren MM, Cavaillé F, Bottari S, Strosberg AD, Nahmias C. Characterization of membrane glycoprotein having pharmacological and biochemical properties of an AT2 angiotensin II receptor from human myometrium. EurJ Biochem 1994;220:919-26. Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood Pressure. TEM 2008;481:4. Lv P, Miao SB, Shu YN, Dong LH, Liu G, Xie XL, et al. Phosphorylation of smooth muscle 22cx facilitates angiotensin Il—induced ROS production via activation of the PKCö—P47phox axis through release of PKCö and actin dynamics and is associated with hypertrophy and hyperplasia of vascular smooth muscle cells in vitro and in vivo. Circ Res 2012;111:697-707.
Lijnen P, Petrov V. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Mol Cell Cardiol 1999;31 1949-70.
Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin || type receptor research in the cardiovascular system. Brief Review 1999;33:613—21.
Kramer S, Peters H, Mika A, Loof T, Althoff N, Neumayer H, et al. The non—peptide AT2 receptor agonist compound 21 ameliorates hypertrophy and fibrosis in uremia-associated cardiomyopathy. Hypertension 201 O;28:442.
Batenburg WW, Garrelds IM, Bernasconi CC, Jeanneret LJ, van Kats JP, Saxena PR, et al. Angiotensin || type receptor—mediated vasodilation in human coronary microarteries. Circulation 2004;109:2296—301.
Parlakplnar H, Yanllmaz M, Ağlamış S, Acet A. Kardiyovasküler sistem ve anjiyotensin || tip reseptörü (AT2). Inönü Universitesi Tıp Fakültesi Dergisi 2004;11:49-52.
Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Lore|| BH. Angiotensin type receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation 1999;99:22-5.
Nio Y, Matsuharj H, Muravuwa S, Kanasaki M, Inada M. Regıılation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. C|in Invest 1995;95:46-54.
Kaschina E, Grzesiak A, Li J, Ludwig AF, Timm M, Rompe F, et al. Angiotensin type receptor stimulation: novel option of therapeutic interference with the reninangiotensin system in myocardial infarction? Circulation 2008;118:2523-32.
Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, et al. AT1 and AT2 receptor gene expression in human heart failure. Circulation 1997;95:1201—6.
Liu Y—H, Yang X—P, Sharov VG, Nass O, Sabah HN, Peterson E, et al. Effect of angiotensin—converting enzyme inhibitors and angiotensin type receptor antagonists in rats with heart failure. C|in Invest 1997;99:1926-35.
Akishita M, Ito M, Lehtonen YJ, Daviet L, Dzau VJ, Horiuchi M. Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. C|in Invest 1999;103(1):63-71.
Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, et al. Cardiac—specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor- mediated pressor and chronotropic effects. Clin Invest 1998;101:527—35.
De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415—72.
Macari D, Bottari S, Whitbread S, De Gasparo M, Levens N. Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium— depleted rat. EurJ Pharmacol 1993;249:85-93.
Barber MN, Sampey DB, Widdop RE. AT2 Receptor Stimulation Enhances Antihypertensive effect of AT1 receptor antagonist in hypertensive rats. Hypertension 1999;34:1112-6.
Falcon BL, Veerasingham SJ, Sumners C, Raizada MK. Angiotensin type receptor mediated gene expression profiling in human coronary artery endothelial cells. Hypertension 2005;45:692—7.
Zhu L, Carretero OA, Liao TD, Harding P, Li H, Sumners C, et al. Role of prolylcarboxypeptidase in angiotensin type receptormediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 201 O;56:384—90.
Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. Clin Invest 1995;95:46—54.
Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993;73:439—47.
Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, et al. Angiotensin type receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997;96:3954—62.
Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas |, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747—52.
Kim 5, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001;103:148—54.
Liu Y-H, Yang X—P, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin type receptor antagonists in rats with heart failure: role of kinins and angiotensin type receptors. Clin Invest 1997;99:1926-35.
Wang CH, Li F, Takahashi N. The renin angiotensin system and the metabolic syndrome. Open Hypertens 2010;3:1—13.
Minshall RD, Nakamura F, Becker RP, Rabito SF. Characterization of bradykinin BZ receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res 1995;76:773—80.
Yayama K, Nagaoka M, Takano M, Okamoto H. Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes. Biochim Biophys Acta 2000 Jan 10;1495(1):69-77.
Yang X—P, Liu Y—H, Scicli GM, Webb CR, Carretero OA. Role of kinins in the cardioprotective effect of preconditioning. Study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen—deficient rats. Hypertension 1997;30:735—40.
Liu YH, Yang XP, Shesely EG, Sankey SS, Carretero OA. Role of Angiotensin type receptors and kinins in the cardioprotective effect of angiotensin II type receptor antagonists in rats with heart failure. JACC 2004;43(8):1473—80.
Yamada Y, Yamauchi D, Yokoo M, Ohinata K, Usui H, Yoshikawa M. potent hypotensive peptide, novokinin, induces relaxation by ATz- and IP—receptor—dependent mechanism in the mesenteric artery from SHRs. Biosci Biotechnol Biochem 2008;72:257—9. 190 . Wan YQ, WalIinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT(2) receptor agonist. Med Chem 2004;47:5995—6008.
Wan Y, Wallinder C, Johansson B, Holm M, Mahalingam AK, Wu X, et al. First reported nonpeptide AT1 receptor agonist (L—162,313) acts as an AT2 receptor agonist in vivo. Med Chem 2004;47:1536—46.
Blankley CJ, Hodges JC, Klutchko SR, Himmelsbach RJ, Chucholowski A, Connolly CJ, et al. Synthesis and structure—activity relationships of novel series of non— peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. Med Chem 1991;34:3248—60.
Gendron L, Laflamme L, Rivard N, AsseIin C, Payet MD, Gallo—Payet N. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen—activated protein kinase) to induce morphological neuronal differentiation in NG108—15 cells. Mol Endocrinol 1999;13:1615—26.
Laflamme L, De Gasparo M, Gallo JM, Payet MD, Gallo— Payet N. Angiotensin induction of neurite outgrowth by AT2 receptors in NG108—15 cells. Effect counteracted by the AT1 receptors. Biol Chem 1996;271:22729—35.
Gendron L, Cote F, Payet MD, Gallo—Payet N. Nitric oxide and cyclic GMP are involved in angiotensin II AT(2) receptor effects on neurite outgrowth in NG108—15 cells. Neuroendocrinology 2002;75:70—81.
Busche S, Gallinat S, Bohle RM, Reinecke A, Seebeck J, Franke F, et al. Expression of AT1 and AT2 receptors in adult rat cardiomyocytes after myocardial infarction: single—cell RT—PCR study. Am Pathol 2000;157:605—1 1.
Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M. Distribution of angiotensin II receptor subtypes in rat heart. Circ Res 1992;71:1482—9.
Matsubara H, Kanasaki M, Murasawa S, Tsukaguchi Y, Nio Y, Inada M. Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture. Clin Invest 1994;93:1592— 601.
Unger T. The angiotensin type receptor: variations on an enigmatic theme. Hypertens1999;17:1775-86.
Rogg H, De Gasparo M, Graedel E, Stulz P, Burkart F, Eberhard M, et al. Angiotensin II receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur HeartJ 1996;17:1112—20.
Wharton J, Morgan K, Rutherford RA, Catravas JD, Chester A, Whitehead BF, et al. Differential distribution of angiotensin AT2 receptors in normal and failing human heart. Pharmacol Exp Ther 1998;284:323— 36.
Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, et al. Angiotensin type receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997;96:3954—62.
Voros S, Yang Z, Bove CM, Gilson WD, Epstein FH, French BA, et al. Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. Am Physiol Heart Circ Physiol 2006;290:1004-10.
Jugdutt BI, Menon V. AT1 Receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Mol Cell Biochem 2004;260:111—8.
Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post—myocardial infarction remodeling. Life Sci 2006;80:82—88.
Adachi Y, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, et al. Angiotensin type receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 2003;107;2406-8.
Oishi Y, Ozono R, Yano Y, Teranishi Y, Akishita M, Horiuchi M, et al. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 2003;41:814—8.
Heerding JN, Hines J, Fluharty SJ, Yee DK. Identification and function of disulfide bridges in the extracellular domains of the angiotensin type receptor. Biochemistry 2001 ;40:8369-77.
Whitebread S, Mele M, Kamber B, De Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989;163:284-91.
Utsunomiyaa H, Nakamuraa M, Kakudob K, Inagamia T, Tamuraa M. Angiotensin || AT2 receptor localization in cardiovascular tissues by its antibody developed in AT2 gene—deleted mice. Regul Pept 2005;126:155—61.
Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, et al. Non—peptide AT2—receptor agonists. Curr Opin Pharmacol 2010;11:1—6.
Bosnyak S, Welungodal K, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non—peptide agonist, compound21, evokes vasodepressor effects inconscious spontaneously hypertensive rats. Br Pharmacol 2010;159:709-16.